Eagle Pharmaceuticals Inc(NASDAQ:EGRX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $40.92M. Analysts estimated a revenue of $40.80M. Earnings per share were $0.80. Analysts had estimated an EPS of $0.71.
In a different note, On Jun 20, 2016, Mizuho Securities said it Downgrades its rating on Eagle Pharmaceuticals Inc. The shares have been rated ‘Neutral’ by the firm.
Eagle Pharmaceuticals Inc (EGRX) shares turned negative on Wednesdays trading session with the shares closing down -1.04 points or -1.68% at a volume of 3,71,501. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $61.83. The peak price level was also seen at $61.83 while the days lowest was $60. Finally the shares closed at $60.8. The 52-week high of the shares is $102.48 while the 52-week low is $33.02. According to the latest information available, the market cap of the company is $951 M.
Several Insider Transactions has been reported to the SEC. On Apr 5, 2016, Scott Tarriff (President and CEO) sold 30,765 shares at $40.63 per share price.Also, On Mar 16, 2016, Michael Graves (director) purchased 1,000 shares at $56.73 per share price.On Dec 23, 2015, Sander A Flaum (director) sold 13,025 shares at $67.88 per share price, according to the Form-4 filing with the securities and exchange commission.
Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.